Successful antibody screening study
Therapeutic antibody supplier MorphoSys and technology company Biametrics will continue their collaboration in the area of high-throughput antibody screening following a successful feasibility study.
Biametrics performed the screening study using MorphoSys’ reagents and its own microarray-based b-screen device, recently launched for high-throughput biomolecular interaction screening/analysis, for the characterisation of Fab fragment antigen interactions. The study demonstrated the advantages of b-screen to speed up the overall antibody screening process using the microarray format.
The b-screen device enables the detection of biomolecules in a high-density array format on microscope slide disposables. No fluorescence labels are needed for readout, which leads to minimised sample pre-treatment and reagent consumption. The optical detection method makes it possible to reduce the complexity of the conventional label-free assays while enhancing the throughput and maintaining precision and reliability.
“We have identified b-screen as a promising technology in the field of epitope mapping and will now broaden our collaboration with Biametrics,” said Dr Markus Enzelberger, Senior VP, Head of Discovery Alliances & Technologies at MorphoSys.
Light-powered DNA detection removes the need for PCR
Unlike PCR, which amplifies DNA sequences by making millions of copies of target DNA for...
Early Parkinson's detection with an RNA-based blood test
The test has the potential to alleviate the uncertainty faced by patients and clinicians,...
Biomarkers for SIDS found in blood samples
US researchers have revealed the fingerprints of sudden infant death syndrome (SIDS) within blood...
